Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Exploring Psilocybin Treatments in Underserved Indications

Rhea-AI Summary

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announced a broadcast titled "Psychedelics — Not Just for Mental Health Anymore." The company's research into psilocybin's potential extends beyond depression to treat chronic pain and eating disorders. Tryp aims to develop synthetic psilocybin as a treatment option for neuropsychiatric disorders, with its lead candidate, TRP-8802, targeting fibromyalgia. Additionally, Tryp plans a phase 2a clinical study for eating disorders. The firm emphasizes its experienced management team in advancing drug candidates.

Positive

• Aiming to expand psilocybin research beyond depression to chronic pain and eating disorders.
• Lead candidate TRP-8802 targets fibromyalgia, a condition affecting over five million in the U.S.
• Plans for a phase 2a study for eating disorders in collaboration with University of Florida.

Negative

• None.

NEW YORK, July 30, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announces the availability of a broadcast titled, “Psychedelics — Not Just for Mental Health Anymore.”

To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast

To view the full editorial, please visit: https://nnw.fm/i3ouS

While it is common knowledge that the use of psychedelic medicines such as peyote and psilocybin to produce healing effects dates back thousands of years, modern-day research was stymied by the Controlled Substances Act of 1970 that classified psychedelics as Schedule I drugs with no medical use. In the last few years, the stigma has been lifted, and research has accelerated with some promising results, such as Johns Hopkins Medicine showing that two doses of psilocybin, the psychoactive compound in “magic” mushrooms, in combination with psychotherapy produced a reduction in symptoms for adults with major depression.

While depression is a hot-button indication for several different psychedelic companies, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is confident that psilocybin can be effective in treating several other underserved indications, namely chronic pain and certain eating disorders. The San Diego-based company has assembled a seasoned management team and group of world-class advisors to lend their expertise in developing new drug candidates for chronic pain and eating disorders as part of Tryp’s Psilocybin-for-Neuropsychiatric Disorders, or PFN program.

About Tryp Therapeutics Inc.

Tryp Therapeutics is a pharmaceutical company focused on developing compounds with known activity and safety profiles for the treatment of rare and other diseases with unmet medical needs. Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain neuropsychiatric-based disorders. Tryp’s lead PFN drug candidate is TRP-8802 for the treatment of fibromyalgia, a chronic pain syndrome estimated to affect more than five million people in the United States. The company is also preparing to initiate a phase 2a clinical study for eating disorders in partnership with the Dr. Jennifer Miller at the University of Florida. In addition to its PFN program, Tryp is developing TRP-1001, an oral formulation of razoxane for the treatment of soft-tissue sarcoma. Soft-tissue sarcomas are a rare and diverse group of tumors that account for about 1% of all cancers in adults and 7% in children. Based on the prevalence of soft-tissue sarcomas in the United States, Tryp believes it is a rare disease and that TRP-1001 should qualify for orphan drug status.

For more information about the company, please visit www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYP are available in the company’s newsroom at https://ibn.fm/TRYPF.

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

FAQ

What recent announcement did Tryp Therapeutics (TRYPF) make regarding psilocybin research?

Tryp Therapeutics announced a broadcast highlighting psilocybin's potential beyond mental health, focusing on chronic pain and eating disorders.

What is the focus of Tryp Therapeutics' PFN program?

The PFN program focuses on developing synthetic psilocybin for neuropsychiatric disorders, particularly targeting chronic pain and eating disorders.

What is TRP-8802 and what condition does it target?

TRP-8802 is Tryp's lead candidate for treating fibromyalgia, a chronic pain syndrome.

Is Tryp Therapeutics (TRYPF) planning any clinical studies?

Yes, Tryp is planning to initiate a phase 2a clinical study for eating disorders.